- Home
- TIC vs EVO Comparison
TIC vs EVO Comparison
Compare TIC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIC
- EVO
- Stock Information
- Founded
- TIC 1991
- EVO 1993
- Country
- TIC United States
- EVO Germany
- Employees
- TIC N/A
- EVO N/A
- Industry
- TIC
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- TIC
- EVO Health Care
- Exchange
- TIC Nasdaq
- EVO Nasdaq
- Market Cap
- TIC 1.5B
- EVO 1.5B
- IPO Year
- TIC N/A
- EVO 2021
- Fundamental
- Price
- TIC $10.64
- EVO $4.30
- Analyst Decision
- TIC Hold
- EVO Buy
- Analyst Count
- TIC 1
- EVO 2
- Target Price
- TIC $13.00
- EVO $5.90
- AVG Volume (30 Days)
- TIC 223.4K
- EVO 154.6K
- Earning Date
- TIC 05-27-2025
- EVO 05-06-2025
- Dividend Yield
- TIC N/A
- EVO N/A
- EPS Growth
- TIC N/A
- EVO N/A
- EPS
- TIC N/A
- EVO N/A
- Revenue
- TIC $1,097,393,000.00
- EVO $851,944,444.00
- Revenue This Year
- TIC $4.52
- EVO $11.29
- Revenue Next Year
- TIC $5.23
- EVO $13.20
- P/E Ratio
- TIC N/A
- EVO N/A
- Revenue Growth
- TIC 4.51
- EVO 1.50
- 52 Week Low
- TIC $8.76
- EVO $2.84
- 52 Week High
- TIC $14.28
- EVO $5.68
- Technical
- Relative Strength Index (RSI)
- TIC N/A
- EVO 61.35
- Support Level
- TIC N/A
- EVO $3.91
- Resistance Level
- TIC N/A
- EVO $4.38
- Average True Range (ATR)
- TIC 0.00
- EVO 0.13
- MACD
- TIC 0.00
- EVO 0.01
- Stochastic Oscillator
- TIC 0.00
- EVO 86.89
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.